A Bibliometric Study on Second-generation Antipsychotic Drugs in the Asia-Pacific Region

Journal of Experimental and Clinical Medicine (Taiwan)

Volumn 6, Issue 4, 2014, Pages 111-117

  López Muñoz, Francisco ^a,b,c   Shen, Winston W ^d   Shinfuku, Naotaka ^e,f   Pae, Chi Un ^g,h   Castle, David J ⁱ   Chung, Albert K ^j   Sim, Kang ^k   Álamo, Cecilio ^b  

^a CAMILO JOSÉ CELA UNIVERSITY   (Spain)

^b UNIVERSITY OF ALCALÁ   (Spain)

^c Neuropsychopharmacology Unit Hospital 12 de Octubre Research Institute ^*  (Spain)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e KOBE UNIVERSITY   (Japan)

^f SEINAN GAKUIN UNIVERSITY   (Japan)

^g The Catholic University of Korea College of Medicine   (South Korea)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF MELBOURNE   (Australia)

^j QUEEN MARY HOSPITAL   (Hong Kong)

^k INSTITUTE OF MENTAL HEALTH   (Singapore)

more..

Author keywords

Atypical antipsychotic drug; Bipolar disorder; Risperidone; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ASENAPINE; BLONANSERIN; CLOZAPINE; ILOPERIDONE; LURASIDONE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PEROSPIRONE; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE; ZOTEPINE;

AUSTRALIA; BIBLIOMETRICS; BIPOLAR DISORDER; CLINICAL INDICATOR; DATA ANALYSIS; DRUG APPROVAL; ECONOMIC DEVELOPMENT; GROSS NATIONAL PRODUCT; HEALTH CARE COST; HONG KONG; HUMAN; JAPAN; MEDICAL LITERATURE; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SINGAPORE; SOCIOECONOMICS; SOUTH KOREA; TAIWAN;

EID: 84905733406     PISSN: 18783317     EISSN: 18783325     Source Type: Journal    
DOI: 10.1016/j.jecm.2014.06.001     Document Type: Review

References (31)

1. López-Muñoz F., Álamo C. Neurobiological background for the development of new drugs in schizophrenia. Clin Neuropharmacol 2011, 34:111-126.
2. López-Muñoz F., Shinfuku N., Shen W.W., Moreno R., Molina J.D., Rubio G., Huelves L., et al. Thirty years of scientific research on second-generation antipsychotic drugs in Japan: a bibliometric analysis. Open J Psychiatry 2013, 3:18-25.
3. López-Muñoz F., Shen W.W., Pae C.U., Moreno R., Rubio G., Molina J.D., Noriega C., et al. Trends in scientific literature on atypical antipsychotics in South Korea: a bibliometric study. Psychiatry Invest 2013, 10:8-16.
4. López-Muñoz F., Shen W.W., Moreno R., Molina J.D., Noriega C., Pérez-Nieto M.A., Rubio G., et al. International scientific productivity on second-generation antipsychotic drugs in Taiwan: a bibliometric study. Taiwanese Journal of Psychiatry (Taipei) 2012, 26:114-129.
5. López-Muñoz F., Chung A.K., Shen W.W., Huelves L., Noriega C., Rubio G., Molina J.D., et al. Abibliometric study of scientific research on second-generation antipsychotic drugs in Hong Kong. Clin Exp Pharmacol 2013, 3:124.
6. López-Muñoz F., Sim K., Shen W.W., Huelves L., Moreno R., Molina J.D., Rubio G., et al. Abibliometric study of scientific research conducted on second-generation antipsychotic drugs in Singapore. Singapore Med J 2014, 55:24-33.
7. López-Muñoz F., Castle D.J., Shen W.W., Moreno R., Huelves L., Pérez-Nieto M.A., Noriega C., et al. The Australian contribution to the literature on atypical antipsychotic drugs: a bibliometric study. Australas Psychiatry 2013, 21:343-345.
8. Price D.J.S. Little science, big science 1963, Columbia University Press, New York, NY.
9. Bradford S.C. Documentation 1948, Crosby Lockwood, London, UK.
10. Shen W.W. Clinical Psychopharmacology for the 21 Century, the Third Edition [in Mandarin] 2011, Ho-Chi Publishing Company, Taipei.
11. Fountoulakis K.N., Nimatoudis I., Iacovides A., Kaprinis G. Off-label indications for atypical antipsychotics: a systematic review. Ann Gen Hosp Psychiatry 2004, 3:4-14.
12. Warren C.R., Serrato J.J., Marguire G.A. Off-label use of second generation antipsychotic drugs. Taiwanese Journal of Psychiatry (Taipei) 2012, 26:162-176.
13. Clement S., Singh S., Burns T. Status of bipolar disorder research. Br J Psychiatry 2003, 182:148-152.
14. Bai Y.M. Pharmacological studies on patients with schizophrenia in Taiwan: a compilation of literature. Taiwanese Journal of Psychiatry (Taipei) 2012, 26:6-18.
15. Shinfuku N. Research on Asian prescription patterns (REAP): focusing on data from Japan. Taiwanese Journal of Psychiatry (Taipei) 2014, 28:71-85.
16. Chong M.Y., Tan C.H., Shinfuku N., Yang S.Y., Sim K., Fujii S., Si T., et al. Prescribing antipsychotic drugs for inpatients with schizophrenia in Asia: comparison of REAP-2001 and REAP-2004 studies. Asia-Pacific Psychiatry 2010, 2:77-84.
17. Nakano W., Yoshimura R., Yang S. The characteristics of pharmacotherapy for inpatients with schizophrenia: a multicentre comparative study in Asia. Eur Neuropsychopharmacol 2010, 20(Suppl.3):S467-S468.
18. Mond J., Morice R., Owen C., Korten A. Use of antipsychotic medications in Australia between July 1995 and December 2001. Aust N Z J Psychiatry 2003, 37:55-61.
19. Stephenson C.P., Karanges E., McGregor I.S. Trends in the utilisation of psychotropic medications in Australia from 2000 to 2011. Aust N Z J Psychiatry 2013, 47:74-87.
20. McGorry P. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry 2005, 39:1-30.
21. Morgan V.A., Waterreus A., Jablensky A., Mackinnon A., McGrath J.J., Carr V., Bush R., et al. People living with psychotic illness in 2010: the second Australian national survey of psychosis. Aust N Z J Psychiatry 2012, 46:735-752.
22. Waghorn G., Saha S., Harvey C., Morgan V.A., Waterreus A., Bush R., Castle D., et al. "Earning and learning" in those with psychotic disorders: the second Australian national survey of psychosis. Aust N Z J Psychiatry 2012, 46:774-785.
23. Xiang Y.T., Wang C.Y., Si T.M., Lee E.H., He Y.L., Ungvari G.S., Chiu H.F., et al. Clozapine use in schizophrenia: findings of the Research on Asia Psychotropic Prescription (REAP) studies from 2001 to 2009. Aust N Z J Psychiatry 2011, 45:968-975.
24. Shinfuku N. What are happening in the mental health system in Japan: some observations. Taiwanese Journal of Psychiatry (Taipei) 2012, 26:70-76.
25. Shimazawa R., Ikeda M. Delays in neurological drug development in Japan. Intern Med 2011, 50:1565-1568.
26. Shimazawa R., Kusumi I., Ikeda M. Delays in psychiatric drug development in Japan. JClin Pharm Ther 2012, 37:348-351.
27. Cheung E.F.C., Lam L.C.W., Hung S.F. Hong Kong. International perspectives on mental health 2011, 96-100. RCPsych Publications, London, UK. H. Ghodse (Ed.).
28. Chong S.A. Mental health in Singapore: a quiet revolution?. Ann Acad Med 2007, 36:795-796.
29. WHO and Ministry of Health and Welfare WHO-AIMS report on mental health system in Republic of Korea 2007, WHO, Gwacheon City.
30. Hwang T.Y., Kim D.H. Republic of Korea's Country Report. Asia-Pacific Community Mental Health Development Project 2008, AAMH, Melbourne, Australia.
31. Sim K., Su H.C., Fujii S., Yang S.Y., Chong M.Y., Ungvari G., Si T., et al. High-dose antipsychotic use in schizophrenia: a comparison between the 2001 and 2004 Research on East Asia Psychotropic Prescription (REAP) studies. Br J Clin Pharmacol 2009, 67:110-117.